主管单位:中华人民共和国
国家卫生健康委员会
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:30.00元
全年:360.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Li Meijie1 Qiu Linjie1 Ren Yan1 Li Jixin1 Zou Chacha2 Wu Zijing2 Zhang Jin1
单位:1中国中医科学院西苑医院治未病中心,北京100091;2北京中医药大学,北京100029
英文单位:1Center for Preventive Treatment of Diseases Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing 100091 China; 2Beijing University of Chinese Medicine Beijing 100029 China
英文关键词:Hypertension;Aggregateindexofsystemicinflammation;Non-overweightornon-obese; Predictivemodel
目的 探究全身炎症综合指数(AISI)与非超重或肥胖人群高血压病的相关性及其预测价值。方法 本研究选取2021年1月1日至2024年9月30日于中国中医科学院西苑医院接受健康体检的非超重或肥胖成年人群8 920例,根据是否患高血压病分为高血压病组和对照组(非高血压病人群)。因AISI呈偏态分布,以对数转换(Log2)进行后续分析,并以是否患高血压病作为分组依据观察基线特征。采用受试者工作特征(ROC)曲线评估AISI对非超重或肥胖人群高血压病的预测效能。结果 8 920例非超重或肥胖受试者中,高血压病患者1 289例(高血压病组),其余均无高血压病(对照组)。高血压病组年龄、体重指数、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、空腹血糖、血肌酐、血尿酸、Log2AISI水平均高于对照组(均P<0.05)。此外,2组饮酒史、糖尿病史、肾脏病史、其他心脑血管疾病史及高血压病家族史比例比较,差异均有统计学意义(均P<0.05)。在连续变量分析中,未经协变量调整的模型1表明,非超重或肥胖个体的Log2AISI每升高1个单位,其高血压病患病风险相应增加24%,即使在完全校正协变量后,该关联依然显著(均P<0.001)。在分类变量分析中,未经协变量调整的模型1结果显示Log2AISI最高四分位数个体高血压病患病风险显著高于最低四分位数个体,且这种关联在完全校正的模型3中持续存在(均P<0.001)。ROC曲线分析结果显示,Log2AISI预测非超重或肥胖人群高血压病发生风险的曲线下面积为0.615(95%置信区间:0.599~0.629)。结论 在非超重或肥胖人群中AISI与高血压病患病风险呈显著的非线性正相关,并具有良好的预测效能,可用于非超重或肥胖人群高血压病的早期诊断。
Objective To explore the correlation and predictive value of the aggregate index of systemic inflammation (AISI) with hypertension in non-overweight or non-obese population. Methods A total of 8 920 non-overweight or non-obese adults who underwent health checkups at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 1, 2021 to September 30, 2024 were enrolled. They were divided into hypertension group and control group (non-hypertensive population) according to the presence of hypertension. Due to the skewed distribution of AISI, logarithmic transformation (Log2) was performed for subsequent analysis, and baseline characteristics were observed with hypertension status as the grouping basis. Receiver operating characteristic (ROC) curve was used to evaluate the predictive efficacy of AISI for hypertension in non-overweight or non-obese population. Results Among 8 920 non-overweight or non-obese subjects, 1 289 were hypertensive patients (hypertension group) and the rest were non-hypertensive (control group). The hypertension group had significantly higher levels of age, body mass index, total cholesterol, triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, serum creatinine, serum uric acid, and Log2 AISI (all P<0.05). In addition, there were statistically significant differences between the two groups in the proportions of drinking history, diabetes mellitus, kidney disease history, other cardio-cerebrovascular disease history, and family history of hypertension (all P<0.05). In the continuous variable analysis, Model 1 without covariate adjustment showed that for each 1-unit increase in Log2AISI in non-overweight or non-obese individuals, the risk of hypertension increased by 24%. This association remained significant even after full adjustment for covariates (both P<0.001). In the categorical variable analysis, Model 1 without covariate adjustment revealed that individuals in the highest quartile of Log2AISI had a significantly higher risk of hypertension than those in the lowest quartile, and this association persisted in the fully adjusted Model 3 (both P<0.001). ROC curve analysis showed that the area under the curve of Log2AISI for predicting the risk of hypertension in non-overweight or non-obese population was 0.615 (95% confidence interval: 0.599-0.629). Conclusion In the non-overweight or non-obese population, AISI is significantly non-linearly and positively correlated with the risk of hypertension and has good predictive efficacy, which can be used for the early diagnosis of hypertension in non-overweight or non-obese individuals.
copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。